Proof Of Concept : Immunogenicity and Safety of hepB Injection in the Dermis Using VAX-ID
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
A proof of concept (POC) study will be conducted in 44 volunteers that have been fully
vaccinated against hepatitis B in the past (at least 5 years ago) to assess the safety and
immunogenicity of intradermal vaccination with hepatitis B surface vaccine antigen using a
newly developed intradermal injection device VAX-ID, compared to intramuscular and
intradermal (Mantoux technique) injection.